1. To ask the First Minister what engagements he has planned for the rest of the day. (S4F-01394)
Official Report · Chamber
Engagements
First Minister’s Question Time
Speakers
Choose an MSP to read only their contributions- Alex Salmond SNP 6
- Johann Lamont Lab 5
- Tricia Marwick 1
The record
12 contributions1. To ask the First Minister what engagements he has planned for the rest of the day. (S4F-01394)
The murder yesterday in London of a member of the armed forces was one of extraordinary brutality and will be condemned by all people who have any sense of humanity. We should remember that one of the purposes of terrorism is to divide communities from each other. Our purpose should be to hold communities together, and that is what we will continue to do.
I fully agree with the First Minister. I believe that he speaks for all of us in the chamber and for those beyond, throughout Scotland, in condemnation of those terrible actions. We are determined to hold together in the face of that terrorism.
Last week, I asked the First Minister about Maureen Fleming. Her immense dignity in challenging the unfair system of accessing cancer drugs captured the attention of the people of Scotland. We know that Maureen met the Cabinet Secretary for Health and Wellbeing, Alex Neil, this morning, at the First Minister’s request. Can we presume that she is now getting the drugs that she needs to prolong her life?
Last week, I asked the First Minister about Maureen Fleming. Her immense dignity in challenging the unfair system of accessing cancer drugs captured the attention of the people of Scotland. We know that Maureen met the Cabinet Secretary for Health and Wellbeing, Alex Neil, this morning, at the First Minister’s request. Can we presume that she is now getting the drugs that she needs to prolong her life?
Certainly, that meeting took place this morning, and I met Mrs Fleming last week. I hope that the situation will be one of the factors that lead us to getting the best possible system of drug distribution in Scotland. It should be our aim and intention to have the best possible system of drug allocation, so that is what we intend to do. I was delighted that Mrs Fleming was able to meet the health secretary this morning.
Of course, we share the First Minister’s aim to get this right in the future, but it is the business of Government to address the problems that Mrs Fleming and others face right now.
On Monday, the health secretary Alex Neil told a radio phone-in programme:
“If the clinicians thought she would benefit from it, she would get the drug”.
Mrs Fleming’s clinician believes that she would benefit from the drug, which is why he prescribed it, and so do many other clinicians who have been consulted about Mrs Fleming’s case. The people who have denied her the drug do not have the same degree of clinical expertise on her condition.
The Health and Sport Committee was told this week that cost was the main issue. Since last week, we have been contacted by other people whose circumstances are similar to those of Mrs Fleming. Whom should they believe? Should they believe the doctors who are at the front line trying to keep people alive, or a Government that has form for misleading the public?
On Monday, the health secretary Alex Neil told a radio phone-in programme:
“If the clinicians thought she would benefit from it, she would get the drug”.
Mrs Fleming’s clinician believes that she would benefit from the drug, which is why he prescribed it, and so do many other clinicians who have been consulted about Mrs Fleming’s case. The people who have denied her the drug do not have the same degree of clinical expertise on her condition.
The Health and Sport Committee was told this week that cost was the main issue. Since last week, we have been contacted by other people whose circumstances are similar to those of Mrs Fleming. Whom should they believe? Should they believe the doctors who are at the front line trying to keep people alive, or a Government that has form for misleading the public?
The Scottish Medicines Consortium was introduced a number of years ago in Scotland—under a different Administration, as it happens. That is our chosen system for deciding which drugs should be allocated. Very demanding formulas need to be used to do that.
Individual patient treatment requests, which are for people who have not had drugs allocated to them within the SMC system, are judged not on economic grounds, but on clinical grounds. The decision is about whether there is something particular to the patient that makes it important that a drug be prescribed.
The system is under review at present—which is well known. We have had the Routledge report, which made some substantial recommendations while accepting that the vast majority of opinion says that the SMC system is robust and effective. We are also looking at the individual patient treatment request system to see whether it can be improved. There have certainly been a number of indications in evidence that improvement is necessary and possible.
It should be remembered that it is simply not the case that individual patient treatment requests are not successful; two thirds of IPTRs are successful. However, improvements are being identified in the system. In particular, the evidence that was given to the Health and Sport Committee this week is very important. There is a consensus that we should not go down the road of having a cancer drugs fund. There was substantial evidence from a range of people and charities, who gave very substantial reasons for why we should not.
That does not mean that we cannot make improvements to the system, and that is what the Cabinet Secretary for Health and Wellbeing and this Administration are determined to do.
I say to Johann Lamont that there cannot be anyone in the chamber—or in the entire country—who does not want the best possible system of drug allocation for Scotland; that is a joint interest for us all. The way in which the Health and Sport Committee is conducting its business is important, because that information will be vital in getting a better system.
Individual patient treatment requests, which are for people who have not had drugs allocated to them within the SMC system, are judged not on economic grounds, but on clinical grounds. The decision is about whether there is something particular to the patient that makes it important that a drug be prescribed.
The system is under review at present—which is well known. We have had the Routledge report, which made some substantial recommendations while accepting that the vast majority of opinion says that the SMC system is robust and effective. We are also looking at the individual patient treatment request system to see whether it can be improved. There have certainly been a number of indications in evidence that improvement is necessary and possible.
It should be remembered that it is simply not the case that individual patient treatment requests are not successful; two thirds of IPTRs are successful. However, improvements are being identified in the system. In particular, the evidence that was given to the Health and Sport Committee this week is very important. There is a consensus that we should not go down the road of having a cancer drugs fund. There was substantial evidence from a range of people and charities, who gave very substantial reasons for why we should not.
That does not mean that we cannot make improvements to the system, and that is what the Cabinet Secretary for Health and Wellbeing and this Administration are determined to do.
I say to Johann Lamont that there cannot be anyone in the chamber—or in the entire country—who does not want the best possible system of drug allocation for Scotland; that is a joint interest for us all. The way in which the Health and Sport Committee is conducting its business is important, because that information will be vital in getting a better system.
The point that we are making to the First Minister is that the system is not working. Examples such as Mrs Fleming’s case mean that it is simply not working, and we need to address that problem. We are seeking reassurance that such decisions are made on clinical grounds and not on ground of cost.
The First Minister has said that Mrs Fleming has been refused the drug on clinical grounds. Let us look at the case. Last week, the First Minister told members in the chamber that Mrs Fleming could not get cetuximab because she had had chemotherapy, and the health secretary, Alex Neil, has repeated that. Alex Neil told the BBC that there were
“a number of conditions suggested by the drug company Merck. One of those conditions is that anyone who has had chemotherapy will not get this drug.”
Why would Mrs Fleming’s doctor prescribe the drug for her if she was precluded? Why would he appeal that decision?
We contacted Merck Serono Ltd, and it issued, at five to 10 this morning, a statement that says:
“Cetuximab has been proven to be effective and is licensed for use in bowel cancer patients previously treated with chemotherapy, and is widely used for such patients in England.”
Whom should we believe—the clinicians who seek to prescribe the drug, the company that manufactures the drug, or Alex Neil?
The First Minister has said that Mrs Fleming has been refused the drug on clinical grounds. Let us look at the case. Last week, the First Minister told members in the chamber that Mrs Fleming could not get cetuximab because she had had chemotherapy, and the health secretary, Alex Neil, has repeated that. Alex Neil told the BBC that there were
“a number of conditions suggested by the drug company Merck. One of those conditions is that anyone who has had chemotherapy will not get this drug.”
Why would Mrs Fleming’s doctor prescribe the drug for her if she was precluded? Why would he appeal that decision?
We contacted Merck Serono Ltd, and it issued, at five to 10 this morning, a statement that says:
“Cetuximab has been proven to be effective and is licensed for use in bowel cancer patients previously treated with chemotherapy, and is widely used for such patients in England.”
Whom should we believe—the clinicians who seek to prescribe the drug, the company that manufactures the drug, or Alex Neil?
In the last part of her question, Johann Lamont—perhaps unintentionally—put her finger on the real issue, which is that we should not be in a position in which politicians decide which drugs are, or are not, allocated. That is why we set up the SMC system in the first place, and why individual patient treatment requests are clinically determined. That is the point and purpose of the system.
The SMC’s decision on licensing cetuximab for prescription came in January 2010. The SMC made clear that
“The submitting company has requested that SMC review a niche within the licensed indication specifically for patients who have not previously received chemotherapy for their ... disease. The efficacy and safety data presented reflects this niche.”
There is no doubt that that was the basis on which the drug was submitted and approved by the SMC. Incidentally, those are the same guidelines that have been used in England by the National Institute for Health and Care Excellence.
It is also the case that, because there is a cancer drugs fund in England, one can get the drug through that means, but it is certainly not—even on those conditions—licensed for everyone. The guidance says that the drug is for specific conditions and that there are restrictions on its use. There is no guarantee that patients with that cancer type would receive the drug through the cancer drugs fund.
Other serious questions—of which Johann Lamont must be aware—about the cancer drugs fund came up in evidence this week. There is a huge consensus that we should not go down that route in Scotland. However, it is possible—and relevant—that we can make improvements in both the SMC system and the individual patient treatment request system. We should certainly do that, and find the best possible system for the distribution of cancer drugs and drugs for other serious diseases.
The SMC’s decision on licensing cetuximab for prescription came in January 2010. The SMC made clear that
“The submitting company has requested that SMC review a niche within the licensed indication specifically for patients who have not previously received chemotherapy for their ... disease. The efficacy and safety data presented reflects this niche.”
There is no doubt that that was the basis on which the drug was submitted and approved by the SMC. Incidentally, those are the same guidelines that have been used in England by the National Institute for Health and Care Excellence.
It is also the case that, because there is a cancer drugs fund in England, one can get the drug through that means, but it is certainly not—even on those conditions—licensed for everyone. The guidance says that the drug is for specific conditions and that there are restrictions on its use. There is no guarantee that patients with that cancer type would receive the drug through the cancer drugs fund.
Other serious questions—of which Johann Lamont must be aware—about the cancer drugs fund came up in evidence this week. There is a huge consensus that we should not go down that route in Scotland. However, it is possible—and relevant—that we can make improvements in both the SMC system and the individual patient treatment request system. We should certainly do that, and find the best possible system for the distribution of cancer drugs and drugs for other serious diseases.
I absolutely do not dispute that it should not be for politicians to decide whether someone gets a drug or not, but the cases should be clinically decided. I do not think that the First Minister listened to me. Clinicians in large number believe that Mrs Fleming’s case is suitable, and the drug company says that the drug is suitable. The only person who is now saying that it was somehow a clinical decision is the First Minister himself. His point that Mrs Fleming does not qualify because she had chemotherapy has been disputed and denied by clinicians who understand her case.
Mrs Fleming’s case was first raised eight months ago and another letter was sent to Alex Neil six weeks ago, but she received a reply and was offered a meeting only after her case was raised in this chamber. People may recall that Ian Morrison was refused treatment until his case was highlighted in the chamber, but he is now getting the cetuximab that he needs, despite his having previously had chemotherapy.
Maisie Black needed a rare drug, but it was not until she was on the front page of the Daily Record that a £21 million fund for orphan drugs was established. We recall John McGarrity, who was ignored on a trolley for eight hours, but once his experience made it into the papers, £50 million was conjured out of thin air to deal with a problem that we were initially told did not exist anyway.
That is no way to run a health service. We all agree that the NHS should be free at the point of need, but is it not the case that, for too many patients, the health service becomes free only at the point that it embarrasses the First Minister?
Mrs Fleming’s case was first raised eight months ago and another letter was sent to Alex Neil six weeks ago, but she received a reply and was offered a meeting only after her case was raised in this chamber. People may recall that Ian Morrison was refused treatment until his case was highlighted in the chamber, but he is now getting the cetuximab that he needs, despite his having previously had chemotherapy.
Maisie Black needed a rare drug, but it was not until she was on the front page of the Daily Record that a £21 million fund for orphan drugs was established. We recall John McGarrity, who was ignored on a trolley for eight hours, but once his experience made it into the papers, £50 million was conjured out of thin air to deal with a problem that we were initially told did not exist anyway.
That is no way to run a health service. We all agree that the NHS should be free at the point of need, but is it not the case that, for too many patients, the health service becomes free only at the point that it embarrasses the First Minister?
Because of the issue’s importance, because we are discussing individual patients and because of the nature of the discussion, I will not even begin to rise to that bait. That is not how such things should be discussed.
Let me just take Johann Lamont through the situation. The SMC licenses cetuximab as it does because the drugs company made that specific request, so it was licensed on that condition. That is where the chemotherapy aspect comes in; it is not applied in individual patient requests, which by definition are to apply a drug to a particular patient for particular reasons, which are outside the SMC licensing process. That also is part of the system. Therefore, Johann Lamont should take the point that the conditions on which the SMC licensed cetuximab were identical to the conditions—[Interruption.] They were identical to the conditions on which the NICE system licensed the drug in England. That was the request that was made.
An individual patient treatment request decision is based on clinical grounds and on the specific characteristics of the individual patient, which are also clinically judged. Of the individual patient treatment requests for cancer drugs, two thirds are accepted. Nowhere in the process that I have identified is there any intervention from the health secretary, the First Minister or any other politician. Those matters are determined clinically .
On the orphan drugs fund, Johann Lamont does herself no credit by not welcoming that announcement. If she cares to remember, the announcement was based on a clinical recommendation that arose from the Routledge review. Therefore, the health secretary acted to set up such a fund.
The overwhelming body of evidence—I can quote expert after expert, from Professor David Webb, Eric Low, the east of Scotland cancer research network representative, and Leigh Smith of Melanoma Action and Support Scotland, who all gave evidence to this week’s Health and Sport Committee meeting explaining this point in substantial detail—is that a cancer drugs fund is not the way that we should proceed in Scotland. [Interruption.]
Let me just take Johann Lamont through the situation. The SMC licenses cetuximab as it does because the drugs company made that specific request, so it was licensed on that condition. That is where the chemotherapy aspect comes in; it is not applied in individual patient requests, which by definition are to apply a drug to a particular patient for particular reasons, which are outside the SMC licensing process. That also is part of the system. Therefore, Johann Lamont should take the point that the conditions on which the SMC licensed cetuximab were identical to the conditions—[Interruption.] They were identical to the conditions on which the NICE system licensed the drug in England. That was the request that was made.
An individual patient treatment request decision is based on clinical grounds and on the specific characteristics of the individual patient, which are also clinically judged. Of the individual patient treatment requests for cancer drugs, two thirds are accepted. Nowhere in the process that I have identified is there any intervention from the health secretary, the First Minister or any other politician. Those matters are determined clinically .
On the orphan drugs fund, Johann Lamont does herself no credit by not welcoming that announcement. If she cares to remember, the announcement was based on a clinical recommendation that arose from the Routledge review. Therefore, the health secretary acted to set up such a fund.
The overwhelming body of evidence—I can quote expert after expert, from Professor David Webb, Eric Low, the east of Scotland cancer research network representative, and Leigh Smith of Melanoma Action and Support Scotland, who all gave evidence to this week’s Health and Sport Committee meeting explaining this point in substantial detail—is that a cancer drugs fund is not the way that we should proceed in Scotland. [Interruption.]
Tricia Marwick
The Presiding Officer · Mid Fife and Glenrothes
link
Order.
Those experts said that they believe that the cancer drugs fund will not be renewed in England because of its faults and failures.
However, what we can do in Scotland is find a better system in respect of the SMC and take forward the recommendations of the Routledge review. I also believe that we can find a better system for individual patient treatment requests. As we get to that system, I hope that we will all remember the joint ownership of the current system, which was not devised by this Government but was inherited by us. As we improve that system, as we are duty bound to do as parliamentarians who represent our constituents and as human beings who genuinely care about the health of Scotland, I hope that we will have the support of the Parliament on a non-party-political basis.
However, what we can do in Scotland is find a better system in respect of the SMC and take forward the recommendations of the Routledge review. I also believe that we can find a better system for individual patient treatment requests. As we get to that system, I hope that we will all remember the joint ownership of the current system, which was not devised by this Government but was inherited by us. As we improve that system, as we are duty bound to do as parliamentarians who represent our constituents and as human beings who genuinely care about the health of Scotland, I hope that we will have the support of the Parliament on a non-party-political basis.
Motions, questions and votes
Linked from this item of the Official ReportIn this meeting
Everything on 23 May 2013 →- Flooding (Fife) Questions · 4
- Fuel Poverty Questions · 7
- Film and Television Industry Questions · 4
- Social Housing (New Homes) Questions · 5
- Rail Passenger Franchise Questions · 6
- Housing (Tenant Deposit Schemes) Questions · 4
- Waste Incineration (Health Implications) Questions · 4
- Independence (Corporation Tax) Questions · 4
- Transport Budget (Walking and Cycling) Questions · 6
- Engagements First Minister’s Questions · 12
- Prime Minister (Meetings) First Minister’s Questions · 13
- Cabinet (Meetings) First Minister’s Questions · 6
- Independence (Protection for Savers and Pensioners) First Minister’s Questions · 4
- Government Grants (Tax Levels) First Minister’s Questions · 4
- Domestic Violence Disclosure Scheme First Minister’s Questions · 4
- Mary Barbour Commemoration Members’ business · 10
- Forth Road Bridge Bill: Stage 3 Bill debate · 28
- Scottish Coal Industry Task Force Statement · 32
- National Trust for Scotland (Governance etc) Bill: Final Stage Bill debate · 14
- Energy Bill Bill debate · 2
- Decision Time Decision time · 3
The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.